Monday , April 22 2019
Breaking News
Home / BUSINESS / Dr. Reddy’s moves up as USFDA completes audit at its subsidiary in Hyderabad
Dr. Reddy’s moves up as USFDA completes audit at its subsidiary in Hyderabad

Dr. Reddy’s moves up as USFDA completes audit at its subsidiary in Hyderabad

Dr. Reddy’s Laboratories is currently trading at Rs. 2759.45, up by 10.55 points or 0.38% from its previous closing of Rs. 2748.90 on the BSE.

The scrip opened at Rs. 2755.00 and has touched a high and low of Rs. 2773.30 and Rs. 2731.10 respectively. So far 7794 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 5 has touched a 52 week high of Rs. 2875.00 on 04-Feb-2019 and a 52 week low of Rs. 1888.00 on 21-May-2018.

Last one week high and low of the scrip stood at Rs. 2775.05 and Rs. 2641.10 respectively. The current market cap of the company is Rs. 45649.87 crore.

The promoters holding in the company stood at 26.77%, while Institutions and Non-Institutions held 45.67% and 13.94% respectively.

USFDA has completed audit of R&D facility of Aurigene Discovery Technologies, a wholly owned subsidiary of Dr. Reddy’s Laboratories, situated at Miyapur, Hyderabad. No FDA 483 was issued at the end of inspection.

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.’

Leave a Reply

Your email address will not be published. Required fields are marked *

*

Inline
Inline